NCT03920267

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 261 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).

Conditions

• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	BMS-986165	Specified dose on specified days

Timeline

• Start date: 2019-03-26
• Primary completion: 2025-03-21
• Completion: 2025-03-21
• First posted: 2019-04-18
• Last updated: 2026-03-20
• Results posted: 2026-03-20

Locations

98 sites across 14 countries: United States, Argentina, Brazil, Canada, Colombia, Hungary, Japan, Mexico, Poland, Romania, Russia, South Korea, Spain, Taiwan

Regulatory

• FDA-regulated drug study